APO-CAPTO TAB 12.5MG 12.5 MG
CAPTOPRIL : 12.5 MG · DIN 00893595 · APOTEX INC
Health Canada status: MARKETED
What is APO-CAPTO TAB 12.5MG?
APO-CAPTO TAB 12.5MG 12.5 MG contains CAPTOPRIL : 12.5 MG. It is listed in the Health Canada Drug Product Database under DIN 00893595, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 31-Dec-1990. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00893595 |
|---|---|
| Brand name | APO-CAPTO TAB 12.5MG |
| Generic / active ingredient | CAPTOPRIL : 12.5 MG |
| Manufacturer | APOTEX INC |
| Strength | 12.5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C09AA01 CAPTOPRIL |
| AHFS class | 24:32.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 31-Dec-1990 |
| Original market date | 1990-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code C09AA01 CAPTOPRIL. 9 of 77 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-CAPTO TAB 100MG | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 00893625 |
| APO-CAPTO TAB 50MG | 50 MG | TABLET | APOTEX INC | MARKETED | DIN 00893617 |
| NOYADA | 25 MG / 5 ML | SOLUTION | ETHYPHARM INC | MARKETED | DIN 02543915 |
| NOYADA | 5 MG / 5 ML | SOLUTION | ETHYPHARM INC | MARKETED | DIN 02543907 |
| TEVA-CAPTOPRIL | 100 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 01942999 |
| TEVA-CAPTOPRIL | 12.5 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 01942964 |
| TEVA-CAPTOPRIL | 25 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 01942972 |
| TEVA-CAPTOPRIL | 50 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 01942980 |
| APO-CAPTO TAB 25MG | 25 MG | TABLET | APOTEX INC | DORMANT | DIN 00893609 |
| APO-CAPTO TAB 6.25MG | 6.25 MG | TABLET | APOTEX INC | DORMANT | DIN 01999559 |
Who else supplies CAPTOPRIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CAPTOPRIL appears in 134 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.